Bafna Pharmaceuticals Ltd.
Snapshot View

155.15 -8.15 ▼-5.0%

23 July 2021, 04:00:00 P.M.
Volume: 6,662

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.bafnapharma.com
Financial Indicators
Market Cap 371.29 Cr.
Earnings per share (EPS) 2.46 Trailing Twelve Months Ending 2021-03
Price-Earning Ratio (PE) 63.72 Trailing Twelve Months Ending 2021-03
Industry PE 35.17 Trailing Twelve Months Ending 2021-03
Book Value / Share 24.00 Trailing Twelve Months Ending 2021-03
Price to Book Value 6.54 Calculated using Price: 156.95
Dividend Yield 0.00 Period Ending 2020-03
No. of Shares Subscribed 2.37 Cr. 23,656,335 Shares
FaceValue 10
Company Profile

Bafna Pharmaceuticals was incepted by Bafna Mahaveer Chand in 1981 as a proprietary concern. It was converted into a public limited company on 28th march 1995. The company started its own manufacturing unit in October 1984.

Bafna Pharmaceuticals started its production with tablets facility and subsequently added capsule and oral syrup facilities respectively. BAFNA always focused on institutional and generic supply to keep its production line busy. It also concentrated on registering its products in the international market.

The present manufacturing facilities of BAFNA is set up at Chennai. The facility for producing Betalactam products was constructed in the year 2001 in a separate block.

It acquired 2.65 acres of factory land in Grantylon village, near Chennai to expand its operations to regulated market like US and UK and also to manufacture its own products.

The company’s vision is to become a leading professionally run global pharma company setting standards across the pharma value chain.

Product Range:

  • Antibacterials
  • Antipyretics
  • Antconvulsants
  • Anxiolytics
  • Pain management
  • Anthelmintics
  • Antifungal
  • Appetite stimulants
  • Antidiarrhoeals
  • Antiemetics
  • Hypnotics
  • Antacids and antiulcerants
  • Vitamin and dietery preparation
  • Cough and cold preparations
  • Antiasthmatics
  • Calcium preparations
  • Antihypertensives
  • Antidiabetics

Achievements/ Awards:

  • BAFNA was awarded the WHO GMP in the year 1995.
  • Bagged the ‘Best Supplier Award’ from the State Pharmaceutical Corporation of Sri Lanka on 30th July 2005.
  • Accorded the status of an ‘Export House’ in recognition of its excellent export performance.
  • Received Medicines and Health Care Products Regulatory Agency (MHRA) approval for its Grantlyon facility meant for exports to the UK markets. Bafna was the 35th company in the Indian pharmaceuticals industry (IPI) to receive MHRA approval.
  • 2009 ISO 9001: 2000 Certificate of Registration for Manufacture and Export of Pharmaceutical products
  • MHRA Certificate of GMP Compliances of Manufacturer from Medicines and Healthcare products Regulatory Agency, U.K.
  • 2010 Bafna Pharmaceuticals have been awarded the Gold Quality Excellence Award 2009
  • Bafna Pharmaceuticals have inaugurated its Formulation Research & Development unit (Formulation Facility) in Chennai
  • 2011 Bafna Pharmaceuticals has received Indian Drug Manufacturer's Association (IDMA) Quality Excellence Award 2010 - Silver Award under the category of Formulations Units
  • Bafna Pharmaceuticals has received Udyog Rattan Award and Excellence Award from the Institute of Economic Studies Delhi.

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
-4.99%
1 Week
-5.66%
1 Month
+10.39%
3 Month
+17.94%
6 Month
+16.57%
1 Year
+1415.14%
2 Year
+2272.32%
5 Year
+409.52%
9 years 2012-03 2013-03 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03
Return on Equity (%) 3.95 6.89 2.25 9.22 -18.69 -37.05 -40.37 -64.36 -22.93
Return on Capital Employed (%) 11.00 11.19 9.15 12.56 -0.04 -5.98 -6.97 -20.90 -2.95
Return on Assets (%) 1.21 1.72 0.57 2.99 -6.58 -10.49 -11.17 -15.90 -1.96

Balance Sheet View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Shh. Funds 64 67 69 72 59 45 41 21 51
Non Curr. Liab. 29 29 27 14 39 42 28 29 3
Curr. Liab. 114 147 126 100 87 81 59 71 17
Minority Int.
Equity & Liab. 207 243 223 185 185 167 128 121 71
Non Curr. Assets 72 69 66 68 65 90 79 72 35
Curr. Assets 132 167 149 117 119 77 48 48 36
Misc. Exp. not W/O 3 6 8 1
Total Assets 207 243 223 185 185 167 128 121 71

Profit Loss View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Net Sales 124 167 178 143 85 65 47 44 42
Other Income 1 3 1 1 1 1 31 0 0
Total Income 125 170 179 144 87 66 78 44 43
Total Expenditure -106 -146 -156 -117 -83 -70 -82 -57 -41
PBIDT 19 24 23 26 4 -4 -4 -13 1
Interest -8 -11 -12 -12 -12 -11 -7 -2 0
Depreciation -6 -8 -8 -5 -4 -4 -4 -3 -3
Taxation -3 -1 -1 0 0 1 -2 -2
Exceptional Items 0 -3
PAT 2 4 1 6 -12 -18 -16 -20 -2

Cash Flow View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Cash Fr. Operatn. 28 35 1 9 -3 20 -7 -1 -34
Cash Fr. Inv. -37 -6 -5 56 -1 -14 38 4 33
Cash Fr. Finan. -1 -11 -14 -66 4 -5 -31 -2 7
Net Change -9 18 -18 0 0 0 0 6
Cash & Cash Eqvt 2 21 2 2 3 3 3 3 8

Shareholding Pattern View Details

9 Qtrs 2019-06 (%) 2019-09 (%) 2019-12 (%) 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%)
Promoter 26.36 26.36 26.36 26.40 26.40 92.64 92.64 91.74 90.39
Public 73.64 73.64 73.64 73.60 73.60 7.36 7.36 8.26 9.61
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 51.04 51.04 51.04 50.96 50.96 1.45 1.45 1.47 0.00

Announcements View Details

Thu, 22 Jul 2021
Reg. 34 (1) Annual Report
Pursuant to Regulation 34 (1) of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we are submitting herewith the Annual Report of the Company for the financial year 2020-21 along with Notice of Annual General Meeting which is being sent in electronic mode to the Shareholders of the Company. The said Annual Report 2020-21 has also been updated on the Companys website at www.bafnapharma.com.
Tue, 20 Jul 2021
Shareholding for the Period Ended June 30 2021
Bafna Pharmaceuticals Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30 2021. For more details kindly Click here
Wed, 14 Jul 2021
Statement Of Investor Complaints For The Quarter Ended June 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter
0110
Name of the Signatory :- Jitendra Kumar Pal
Designation :- Company Secretary and Compliance Officer

Technical Scans View Details

Fri, 23 Jul 2021
Decreasing Relative Strength - Benchmark index Decreasing Relative Strength - Benchmark index
Decreasing Relative Strength - Sectoral index Decreasing Relative Strength - Sectoral index
NR 4 Breakdown NR 4 Breakdown
Thu, 22 Jul 2021
Stock Outperforming Benchmark Index in both 1 Week and 3 Month Stock Outperforming Benchmark Index in both 1 Week and 3 Month
Stock Outperforming Sectoral Index in both 1 Week and 3 Month Stock Outperforming Sectoral Index in both 1 Week and 3 Month

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 166,513.85 694.00 +1.0%
Divi's Laboratories Ltd. 128,088.59 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. 90,175.51 5,420.50 +0.7%
Cipla Ltd. 76,510.04 948.50 -0.1%
Cadila Healthcare Ltd. 62,965.29 615.05 -0.9%
Aurobindo Pharma Ltd. 56,484.48 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. 56,291.69 3,915.00 -1.8%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 57.34 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2021-03 64.55 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 46.21 5,420.50 +0.7%
Cipla Ltd. Consolidated 2021-03 31.81 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 29.51 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2021-03 10.59 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 374.38 3,915.00 -1.8%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 3.58 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2021-03 13.78 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 5.15 5,420.50 +0.7%
Cipla Ltd. Consolidated 2021-03 4.17 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 4.85 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2021-03 2.58 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 12.25 3,915.00 -1.8%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 0.18 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2020-03 0.00 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 5,420.50 +0.7%
Cipla Ltd. Consolidated 2020-03 0.18 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 0.35 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2020-03 0.33 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 1.08 3,915.00 -1.8%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 9.66 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2020-03 19.30 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 5,420.50 +0.7%
Cipla Ltd. Consolidated 2020-03 10.09 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 18.30 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.53 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 13.08 3,915.00 -1.8%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 10.07 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2020-03 25.36 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 15.24 5,420.50 +0.7%
Cipla Ltd. Consolidated 2020-03 12.53 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 13.65 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.80 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 17.13 3,915.00 -1.8%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 32,837.50 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2020-03 5,394.42 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 5,420.50 +0.7%
Cipla Ltd. Consolidated 2020-03 17,131.99 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 15,102.20 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2020-03 23,098.51 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 11,246.80 3,915.00 -1.8%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 4,186.79 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2020-03 1,376.54 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 5,420.50 +0.7%
Cipla Ltd. Consolidated 2020-03 1,546.98 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 2,137.60 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2020-03 2,844.69 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 434.90 3,915.00 -1.8%